Abstract

The multiple endocrine neoplasia type 2A (MEN2A) is a monogenic disorder characterized by an autosomal dominant pattern of inheritance which is characterized by high risk of medullary thyroid carcinoma in all mutation carriers. Although this disorder is classified as a rare disease, the patients affected have a low life quality and a very expensive and continuous treatment. At present, MEN2A is diagnosed by gene sequencing after birth, thus trying to start an early treatment and by reduction of morbidity and mortality. We first evaluated the presence of MEN2A mutation (C634Y) in serum of 25 patients, previously diagnosed by sequencing in peripheral blood leucocytes, using HRM genotyping analysis. In a second step, we used a COLD-PCR approach followed by HRM genotyping analysis for non-invasive prenatal diagnosis of a pregnant woman carrying a fetus with a C634Y mutation. HRM analysis revealed differences in melting curve shapes that correlated with patients diagnosed for MEN2A by gene sequencing analysis with 100% accuracy. Moreover, the pregnant woman carrying the fetus with the C634Y mutation revealed a melting curve shape in agreement with the positive controls in the COLD-PCR study. The mutation was confirmed by sequencing of the COLD-PCR amplification product. In conclusion, we have established a HRM analysis in serum samples as a new primary diagnosis method suitable for the detection of C634Y mutations in MEN2A patients. Simultaneously, we have applied the increase of sensitivity of COLD-PCR assay approach combined with HRM analysis for the non-invasive prenatal diagnosis of C634Y fetal mutations using pregnant women serum.

Highlights

  • Multiple endocrine neoplasia type 2 (MEN2) is composed of three clinical subtypes, multiple endocrine neoplasia type 2A (MEN2A), familial medullary thyroid carcinoma, and multiple endocrine neoplasia type 2B, all of which are associated with germline mutations in the RET proto-oncogene

  • Several biochemical tests were used for the early detection of medullary thyroid cancer (MTC) in the past [6], it was the discovery of the correlation between mutations of c-RET and MEN2 syndrome in 1993 that opened a new era in the early recognition of the patients

  • We studied a healthy pregnant woman whose couple suffered the C634Y mutation in heterozygosis and carried a fetus with the MEN2A mutation

Read more

Summary

Introduction

Multiple endocrine neoplasia type 2 (MEN2) is composed of three clinical subtypes, multiple endocrine neoplasia type 2A (MEN2A), familial medullary thyroid carcinoma, and multiple endocrine neoplasia type 2B, all of which are associated with germline mutations in the RET proto-oncogene. Several biochemical tests were used for the early detection of MTC in the past [6], it was the discovery of the correlation between mutations of c-RET and MEN2 syndrome in 1993 that opened a new era in the early recognition of the patients. The DNA-based testing of the c-RET gene on a blood sample offers the opportunity for early identification of the c-RET germline mutations, contributing to the reduction of morbidity and mortality of MEN2 syndrome [7]. The early recognition of the mutant gene carriers makes the prevention and cure of MTC possible, by performing a prophylactic thyroidectomy before the clinical expression of the tumor including genetic counseling [8]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call